About Us
Welcome to Quantix Italia SRL.
We are a leading biotech company in regenerative medicine, founded in 2018 in Milan with the aim of developing and commercializing innovative products to improve patients’ quality of life.
Since our inception, we have achieved significant results, including filing patents and acquiring licenses and exclusive distribution contracts that have ensured rapid expansion in international markets. Each stage of our journey testifies to our commitment to research and development, with the goal of offering safe treatments through validated clinical protocols.
Our solutions stem from a highly innovative approach and are developed with the aim of providing therapeutic solutions for various chronic diseases.
Each treatment offered by our devices integrates the latest technologies available in the field of regenerative medicine, allowing us to respond effectively and purposefully to patients’ health and wellness needs.
Innovative Technology
Our technology platform, developed in collaboration with universities and research centers of excellence, exploits the integration of PRP (platelet-rich plasma), mononuclear cells, and cytokines derived from peripheral blood.
This combination is designed to optimize treatments aimed at promoting anti-inflammatory and angiogenic effects, thereby promoting tissue regeneration and improving therapeutic efficacy in various clinical applications.
Patent Protection
Our company owns and licenses international patents that ensure the exclusivity of drugs, filtration systems and medical devices, offering unique and cutting-edge solutions in the technological and therapeutic landscape.
Infungible Products:
From the Idria platform, designed to achieve a product with proven anti-inflammatory action, to the PROTSMART™ and EXOsmart®, which offer plasma ultrafiltration technologies, our devices are distinguished by high therapeutic efficacy and superior quality standards. The products both used individually and in combination are infungible products.
Mission and Vision
Our mission is to improve the treatment of chronic and inflammatory diseases through biotechnological innovation.
Quantix ‘s vision is to become a global leader in regenerative medicine, improving patients’ lives with sustainable and advanced solutions.
Countries with which we collaborate:
International expansion is essential to Quantix‘s growth.
Through its partnership with Biological Innovations, the company operates in more than 25 countries, bringing its innovative solutions to a global audience.
This international presence not only expands market opportunities, but also stimulates technological and scientific development, strengthening competitiveness and promoting continuous innovation.
- Italy
- Saudi Arabia
- United Arab Emirates
- Poland
- Serbia
- Lebanon
- Czech Republic
- Singapore
- Turkey
- Croatia
- Slovenia
- Israel
- Kuwait
- France
- Spain
- Greece
- Bulgaria
- Taiwan
- India
- Morocco
- Iraq
- Egypt
- Indonesia
- Romania
- Jordan
- Brazil
Our Team
Our Team
The Quantix Italia Srl team is composed of experts in the field of regenerative medicine, biomedical engineering and regulatory consulting. We collaborate closely with renowned research institutions such as the University of Milan and Swiss Stem Cell Biotech in Lugano. Our leadership is supported by deep industry experience and a shared passion for innovation and excellence in patient treatment.
Anne Reid
CEO
Mark Hagne
Lawyer
Diane Miller
Business Manager
Sophie White
Head of Consulting
Paul Goto
Manager
Toby Young
Legal Officer
They say about us
Protsmart™
L'utilizzo di Protsmart™ nei nostri protocolli ha notevolmente migliorato i risultati delle terapie PRP, con pazienti che riferiscono minor dolore e più rapida guarigione.
IDRIA S+
Dopo il trattamento con IDRIA S+, ho notato un miglioramento sostanziale nell'infiammazione e nel dolore al ginocchio.
